|
|
|
|
 |
Volume 21, No. 10
November/December 2005
Feature 1
When, Why and How?
Brugada Syndrome
Chris Gray, MD, FRCPC and John L. Sapp Jr., MD, FRCPC
Feature 2
Reinventing
Cardiac Rehabilitation
James A. Stone, MD, PHD, FRCPC, FAACVPR, FACC
Outside of acute care institutions, cardiovascular disease is a chronic, inflammatory process; the reduction or elimination of recurrent acute coronary syndromes is a major goal of cardiac rehabilitation programs. The success of disease intervention is derived not only from what interventions or therapies are prescribed, but equally from how they are applied.
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
Longer and Longer
Cardio Q & A
Experts Answering Your Questions
1. ECHO accuracy
2. Prevention with statins
3. Lowering BPd
4. The rate solution
CardioCase of the Month
Carolyn Taylor, MD and Krishnan Ramanathan, MD, FRACP
Shot to the Heart:
Cardiac Manifestations of SLE
Cardiovascular News
• Long-term safety of Tracleer® confirmed in PAH
subgroups
• Studies suggest potential metabolic effects of Micardis
• Study finds early statin therapy post-heart attack reduces mortality
• Diovan newly indicated to reduce cardiovascular death
• Report outlines risks and recommendations for CVD
• Pioglitazone reduces risk of CV events in patients with Type 2 diabetes
|
 |
Volume 22, No. 10
October 2005
Feature 1
When, Why and How?
Athletic Heart Syndrome
Aly Abdulla, BSc, MD, LMCC, CCFP(C), DipSportMed (CASM), FCFP (2005)
Feature 2
A Quick Course in
Stroke Prevention
Ashfaq Shuaib, MD, FRCPC, FAHA
Cerebrovascular disease remains a common neurologic problem and its incidence is likely to increase over time. It is strongly recommended that patients be investigated aggressively and the risk factors managed well. Unfortunately, many such individuals continue to be hypertensive or have high cholesterol.
Feature 3
AF in the ER:
Common Scenarios
Evan Lockwood, MD, FRCPC and Bibiana Cujec, MD, FRCPC, FACC
Atrial fibrillation is a common problem with a wide spectrum of presentations. Profiled in this article are five common emergency room scenarios and the management strategies for each.
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
After the Tachycardiat
Cardio Q & A
Experts Answering Your Questions
1. Nitro in CHF
2. Examining ECHO
3. Juice truth
4. ACEI or ARB interference?
CardioCase of the Month
Nitin Ghorpade, MBBS, MCh and Arvind Koshal, MBBS, MS, FRCSC
Cardiac Pseudoaneurysm:
An Uncommon Emergency
Cardiovascular News
• FH update: Treatment reduces CV risk
• New BP-lowering agents better at preventing cardiovascular events
|
 |
Volume 21, No. 8
September 2005
Feature 1
Reducing CV Risk:
What Works?
Sarah A. Ramer, BSc, MD, FRCPC and Jafna L. Cox, BA, MD, FRCPC, FACC
Many pharmacologic and non-pharmacologic therapies in the arsenal of cardiac prevention have been shown to attenuate cardiac risk in selected groups of patients. But who should receive what therapy? How do you decide?
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
Name Your Poisont
Cardio Q & A
Experts Answering Your Questions
1. Looking at lowering digoxin
2. Drug therapy for WCH?
3. Analyzing microalbumenuria
4. PFOs and yearly Dopplers
CardioCase of the Month
Tomas G. Neilan, MD, MRCPI and Davinder S. Jassal, MD, FACC, FRCPC
Syncope: Could It Be Deadly?
|
 |
Volume 21, No. 7
August 2005
Feature 1
ACEI and ARB Combination:
A Promising Solution
Bandar Al Ghamdi, MD and Andrew Ignaszewski, MD, FRCPC
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
The Long and the Short of It
Cardio Q & A
Experts Answering Your Questions
1. Looking at lowering digoxin
2. Drug therapy for WCH?
3. Analyzing microalbumenuria
4. PFOs and yearly Dopplers
CardioCase of the Month
Tomas G. Neilan, MD, MRCPI and Davinder S. Jassal, MD, FACC, FRCPC
Syncope: Could It Be Deadly?
Cardiovascular News
• Clopidogrel highly cost-effective to Canadian health-care setting
• Health Minister helps mark World Hypertension Day
• Study shows heart attack/stroke benefit from intensive cholesterol-lowering
• ATACAND® approved in Canada for treatment of heart failure
• Data shows Micardis® provides superior BP control in early a.m.
• Studies presented on Merck’s investigational drug for Type 2 diabetes
|
 |
Volume 21, No. 6
June 2005
Feature 1
CardioCase of the Month
Cardiac Resynchronization Therapy:
New Hope for Congestive Heart Failure
Bandar Al Ghamdi, MD and Andrew Ignaszewski, MD, FRCPC
Feature 2
2005 Canadian Hypertension Education Program Recommendations
What Are the Key Messages?
On behalf of the Evidence-based Recommendations Task Force of the Candian Hypertension Education Program
As hypertension continues to be a significant public health problem, the Canadian Hypertension Education Program provides its sixth annual revised recommendations for the management of this condition. What’s new this year and what is old, but still important?
What You Need to Know
Peter Lin, MD, CCFP
An FP’s Review of Current Clinical Trials
EUROPA Trial
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
Hiding in Plain Sight
Cardio Q & A
Experts Answering Your Questions
1. Investigating a “funny” feeling
2. Increasing HDL: Is it useful?
3. Indications for ASD closure
Cardiovascular News
• Study shows better outcomes with immediate use of Activase®
• Servier Canada donates to University of Ottawa’s Heart Institute
|
 |
Volume 21, No. 4
April 2005
Feature 1
IHD & Renal Dysfunction:
A Risky Combination
Davinder S. Jassal, MD, FRCPC; Tomas G. Neilan, MD; and Iqbal Bata, MD, LRCPS, FRCPC, FACC
Ischemic heart disease is the world’s leading cause of death. Acute coronary syndromes account for 45% of all-cause mortality in patients with any degree of renal impairment. This article is an update on the current management of ischemic heart disease in patients with renal disease..
Feature 2
Diet Dilemma:
An Examination for CAD
Jean G. Dumesnil CQ, MD, FRCPC, FACC
Maintaining knowledge on the abundant diets available today can prove fruitless. Here is an examination of some of the most recent and most popular diets regarding their efficacy and their relation to obesity, diabetes and hyperlipidemia.
What You Need to Know
Peter Lin, MD, CCFP
An FP’s Review of Current Clinical Trials
PEACE Triall
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
More or Less
Cardio Q & A
Experts Answering Your Questions
1. Why is it that some post-cardiac surgery patients get discharged on clopidogrel and others don’t? What are the guidelines for continuing clopidogrel use?
2. How far do you push ACE inhibitors and ARBs in patients with diabetes who have low blood
Cardiovascular News
• Increasing Lipitor® dosage can reduce cardiovascular events
• Study shows atherothrombosis is seriously undertreated worldwide
• Extensive study finds Aspirin® reduces first stroke risk in women
• Rimonabant improves cardiovascular risk factors in two-year study
• Skin sterol linked to hidden coronary artery disease
• Heart failure preceded by electrical changes
|
 |
Volume 21, No. 3
March 2005
ARTICLES
Feature 1
Atrial Fibrillation
A Breakdown
Chris Gray, MD; and
John Sapp, MD
A trial fibrillation (AF) is becoming an increasinglycommon problem. In this article, we briefly review the complications associated with AF and the various treatment options available to GPs.
The Statin-Intolerant Patient
What to do?
Thomas W. Wilson, MD, FRCPC, FACP
Statins have been touted as safe agents that reduce the risk of cardiovascular events, dementia and osteoporosis. However, one statin was recently withdrawn from the market because of concern over rhabdomyolysis. This
article reviews the efficacy and adverse effects of statins and presents options for statin-intolerant patients.
What You Need to Know
Peter Lin, MD, CCFP
An FP’s Review of Current Clinical Trials
CARDS Trial
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
Go With the Flow
Cardio Q & A
Experts Answering Your Questions
1. What causes an otherwise healthy 30-year-old female to faint when she raises her arms above her head?
2. What are the complications of WPW finding on ECG in a patient with no clinical heart disease?
Cardiovascular News
• Blood clot buster drug studied for treatment of acute ischemic stroke
• New bedside tool gauges mortality risk in heart failure patients
|
 |
Volume 21, No. 2
February 2005
ARTICLES
Feature 1
Advances in
Congestive Heart Failure Care
Michael C.Y. Chan, MBBS, FRCPC, FACC; and Rosa Gutierrez, MN, NP
Heart failure can currently be considered an “epidemic.” This article discusses some of the recent advances in
outpatient management of congestive heart failure.
Feature 2
Hypertension
Screening for Secondary Causes
Carolyn Baer, MD, FRCPC
Most patients seen in primary practice have essential hypertension; however, it is important to recognize features that would point to secondary causes of hypertension and initiate appropriate screening for these patients.
What You Need to Know
Peter Lin, MD, CCFP
An FP’s Review of Current Clinical Trials
ASCOT-LLA Trial
CardioCase of the Month
Carolyn Taylor, MD; and Andrew Ignaszewski, MD, FRCPC;
Picking Out the Pattern
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
It’s a Classic?
Cardio Q & A
Experts Answering Your Questions
It’s a Classic?
1. Should a pacemaker be inserted in patients who become bradycardic when treated with beta blockers for CHF or should the beta blocker be stopped?
2. When is it appropriate to use ezetimibe in cholesterol management?
Cardiovascular News
• Canadian Blood Services’ holiday promotion a success
• ASCOT study shows significant benefit with perindopril
|
 |
Volume 21, No.1
January 2005
ARTICLES
Feature 1
Stroke Prevention
What Are the Options?
A.D. Bell, MD
Stroke is a leading cause of physical disability, functional impairment and mortality. Prevention—through risk factor modification, antiplatelet therapy, immediate management of TIA and carotid endarterectomy—remains the best approach to reducing the stroke burden.
Feature 2
2005 Canadian Hypertension Education Program Recommendations
What Are the Key Messages?
As hypertension continues to be a significant public health problem, the Canadian Hypertension Education Program provides its sixth annual revised recommendations for the management of this condition. What’s new this year and what is old, but still important?
On behalf of the Evidence-based Recommendations Task Force of the Canadian Hypertension Education Program
What You Need to Know
Peter Lin, MD, CCFP
An FP’s Review of Current Clinical Trials
PROVE-IT Trial
CardioCase of the Month
Davinder S. Jassal, MD, FRCPC; Jason D. Yung, MD;
Peter Crofts, MD, FRCPC; and Kier M. Stewart, MD, FRCSC
A Fungal Phenomenon
ECG of the Month
Keith J.C. Finnie, MB, ChB, FRCPC
Transient Tachycardia
Cardio Q & A
Experts Answering Your Questions
1. Is clinical use of ARBs and ACE inhibitors associated with renal failure (i.e., creatinine > 300 µmol/L)?
2. How is a "positive family history for CAD" defined? I think its poor definition leads to increased use of resources.
Cardiovascular News
• Niacin tablets help prevent coronary heart disease
• InterCure’s RESPeRATE® proven to lower blood pressure
|
|
